# US 2017/0283392 A1 · Dibenzazepine derivatives and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0283392 A1
- Document ID: US20170283392A1
- Status: Published application
- Kind: A1
- Application number: 15/623,120
- Filed: 2017-06-14
- Published: 2017-10-05
- Earliest claimed: 2013-12-23
- Assignees: Purdue Pharma L.P.
- Applicants: Purdue Pharma L.P.
- Inventors: Stephen M. Lynch; Laykea Tafesse
- Web page: https://patentgrep.com/patent/US20170283392A1

## CPC

- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 413/04: directly linked by a ring-member-to-ring-member bond
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present disclosure provides dibenzazepine derivatives having Formula I or I(A): and the pharmaceutically acceptable salts and solvates thereof, wherein R3a, R3b, R6, V1, V2, Z1, Z2, Z3, and G are defined as set forth in the specification. The present disclosure is also directed to the use of the compounds of Formula I or I(A), and the pharmaceutically acceptable salts or solvates thereof, to treat a disorder responsive to the blockade of one or more sodium channels. In one embodiment, the compounds of the present disclosure are useful for treating pain.

## Claims

### Claim 1

A compound having Formula I:
or a pharmaceutically acceptable salt thereof,
wherein:
Z1, Z2, and Z3 are each independently selected from the group consisting of N and CR11;
with the proviso that at least one of Z1, Z2, and Z3 is N;
G is selected from the group consisting of hydrogen, dihydroxyalkyl, and —(CHR1a)m—C(═O)E;
m is 0, 1, or 2;
each R1a is independently selected from the group consisting of hydrogen and hydroxy;
E is selected from the group consisting of hydroxy, alkoxy, hydroxyalkyl, and —NR1R2;
R1 is selected from the group consisting of hydrogen, alkyl, aralkyl, (heterocyclo)alkyl, (heteroaryl)alkyl, (amino)alkyl, (alkylamino)alkyl, (dialkylamino)alkyl, (carboxamido)alkyl, (cyano)alkyl, alkoxyalkyl, hydroxyalkyl, and heteroalkyl;
R2 is selected from the group consisting of hydrogen and alkyl; or
R1 and R2 taken together with the nitrogen atom to which they are attached form a 3- to 8-membered optionally substituted heterocyclo;
V1 is —O—
V2 is selected from the group consisting of —W1—C(H)R4d— and —CH2—W2—CH2—;
W1 is selected from the group consisting of —O—, —NR4b—, —C(═O)—, and —CH(R4c)—;
W2 is selected from the group consisting of —O— and NR4b;
R3a is selected from the group consisting of hydrogen, halogen, alkyl, cyano, haloalkyl, hydroxy, alkoxy, and haloalkoxy;
R3b is selected from the group consisting of hydrogen, halogen, alkyl, cyano, haloalkyl, hydroxy, alkoxy, and haloalkoxy;
R4b is selected from the group consisting of hydrogen, alkyl, aralkyl, (heterocyclo)alkyl, (heteroaryl)alkyl, (amino)alkyl, (alkylamino)alkyl, (dialkylamino)alkyl, (carboxamido)alkyl, (cyano)alkyl, alkoxyalkyl, hydroxyalkyl, heteroalkyl, and —COR5b;
R4c is selected from the group consisting of hydrogen and hydroxy;
R4d is hydrogen; or
R4c and R4d taken together with the carbon atoms to which they are attached form a double bond;
R5b is selected from the group consisting of alkyl, cycloalkyl, aryl, and heteroaryl;
R6 is selected from the group consisting of hydrogen, halo, hydroxy, alkyl, hydroxyalkyl, cyano, sulfonamido, heterocyclo, and —X—R7;
X is selected from the group consisting of —O—, —NR8a—, and —(CH2)t—Y—;
Y is selected from the group consisting of —O— and —NR8b—;
t is 1 or 2;
R7 is selected from the group consisting of hydrogen, alkyl, hydroxyalkyl,
R8a is selected from the group consisting of hydrogen and alkyl;
R8b is selected from the group consisting of hydrogen and alkyl; or
R8b and R7 taken together with the nitrogen atom to which they are attached form a 3- to 8-membered optionally substituted heterocyclo;
R9 is selected from the group consisting of hydrogen, alkyl, and hydroxyalkyl;
R10a and R10b are independently selected from the group consisting of hydrogen and alkyl; or
R10a and R10b taken together with the nitrogen atom to which they are attached form a 3- to 8-membered optionally substituted heterocyclo; and
R11 is selected from the group consisting of hydrogen, halogen, alkyl, cyano, haloalkyl, hydroxy, alkoxy, carboxamido, (carboxamido)alkyl, and haloalkoxy.

### Claim 2

A compound having Formula I (A):
or a pharmaceutically acceptable salt thereof,
wherein:
Z1, Z2, and Z3 are each independently selected from the group consisting of N and CR11;
with the proviso that at least one of Z1, Z2, and Z3 is N;
G is selected from the group consisting of hydrogen, dihydroxyalkyl, and —(CHR1a)m—C(═O)E;
m is 0, 1, or 2;
each R1a is independently selected from the group consisting of hydrogen and hydroxy;
E is selected from the group consisting of hydroxy, alkoxy, hydroxyalkyl, and —NR1R2;
R1 is selected from the group consisting of hydrogen, alkyl, aralkyl, (heterocyclo)alkyl, (heteroaryl)alkyl, (amino)alkyl, (alkylamino)alkyl, (dialkylamino)alkyl, (carboxamido)alkyl, (cyano)alkyl, alkoxyalkyl, hydroxyalkyl, and heteroalkyl;
R2 is selected from the group consisting of hydrogen and alkyl; or
R1 and R2, taken together with the nitrogen atom to which they are attached, form a 3- to 8-membered optionally substituted heterocyclo;
V1 is —O—;
V2 is selected from the group consisting of —W2—, —W1—C(H)R4d— and —CH2—W2—CH2—;
W1 is selected from the group consisting of —O—, —NR4b—, —C(═O)—, and —CH(R4c)—;
W2 is selected from the group consisting of —O— and NR4b;
R3a is selected from the group consisting of hydrogen, halogen, alkyl, cyano, haloalkyl, hydroxy, alkoxy, and haloalkoxy;
R3b is selected from the group consisting of hydrogen, halogen, alkyl, cyano, haloalkyl, hydroxy, alkoxy, and haloalkoxy;
R4b is selected from the group consisting of hydrogen, alkyl, aralkyl, (heterocyclo)alkyl, (heteroaryl)alkyl, (amino)alkyl, (alkylamino)alkyl, (dialkylamino)alkyl, (carboxamido)alkyl, (cyano)alkyl, alkoxyalkyl, hydroxyalkyl, heteroalkyl, and —COR5b;
R4c is selected from the group consisting of hydrogen and hydroxy;
R4d is hydrogen; or
R4c and R4d taken together with the carbon atoms to which they are attached form a double bond;
R5b is selected from the group consisting of alkyl, cycloalkyl, aryl, and heteroaryl;
R6 is selected from the group consisting of hydrogen, halo, hydroxy, alkyl, hydroxyalkyl, cyano, sulfonamido, heterocyclo, and —X—R7;
X is selected from the group consisting of —O—, —NR8a—, and —(CH2)t—Y—;
Y is selected from the group consisting of —O— and —NR8b—;
t is 1 or 2;
R7 is selected from the group consisting of hydrogen, alkyl, hydroxyalkyl,
R8a is selected from the group consisting of hydrogen and alkyl;
R8b is selected from the group consisting of hydrogen and alkyl; or
R8b and R7 taken together with the nitrogen atom to which they are attached form a 3- to 8-membered optionally substituted heterocyclo;
R9 is selected from the group consisting of hydrogen, alkyl, and hydroxyalkyl;
R10a and R10b are independently selected from the group consisting of hydrogen and alkyl; or
R10a and R10b taken together with the nitrogen atom to which they are attached form a 3- to 8-membered optionally substituted heterocyclo; and
R11 is selected from the group consisting of hydrogen, halogen, alkyl, cyano, haloalkyl, hydroxy, alkoxy, carboxamido, (carboxamido)alkyl, and haloalkoxy.

### Claim 3 (depends on 2)

The compound of claim 2 having Formula II:
or a pharmaceutically acceptable salt thereof.

### Claim 4 (depends on 2)

The compound of claim 2 having Formula III:
or a pharmaceutically acceptable thereof.

### Claim 5 (depends on 2)

The compound of claim 2 having Formula IV:
or a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 2)

The compound of claim 2 having Formula V:
or a pharmaceutically acceptable salt thereof.

### Claim 7 (depends on 2)

The compound of claim 2, wherein G is dihydroxyalkyl, or a pharmaceutically acceptable salt thereof.

### Claim 8 (depends on 2)

The compound of claim 2, wherein:
G is —(CHR1a)m—C(═O)E;
m is 1 or 2; and
each R1a is hydroxy,
or a pharmaceutically acceptable salt thereof.

### Claim 9 (depends on 2)

The compound of claim 2, wherein G is —(CHR1a)m—C(═O)E and m is 0, or a pharmaceutically acceptable salt thereof.

### Claim 10 (depends on 2)

The compound of claim 2, wherein Z1 is N, Z3 is CH, and R3b is hydrogen, or a pharmaceutically acceptable salt thereof.

### Claim at position 11

11-13. (canceled)

### Claim 14 (depends on 2)

The compound of claim 2, wherein W1 is —CH2—, or a pharmaceutically acceptable salt thereof.

### Claim 15 (depends on 2)

The compound of claim 2, wherein W1 is selected from the group consisting of —NH— and —N(CH3)—, or a pharmaceutically acceptable salt thereof.

### Claim at position 14

16-17. (canceled)

### Claim 18 (depends on 2)

The compound of claim 2, wherein
V1 is —O—;
W1 is —NR4b—; and
R4b is H, alkyl, or (carboxamido)alkyl;
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 19

(canceled)

### Claim 20 (depends on 2)

The compound of claim 2, wherein E is —NH2, or a pharmaceutically acceptable salt or solvate thereof.

### Claim at position 18

21-30. (canceled)

### Claim 31 (depends on 2)

The compound of claim 2 selected from the group consisting of:
(S)-1-(6-(8-(trifluoromethyl)-10,11-dihydrodibenzo[b,f][1,4]oxazepin-2-yl)pyridin-2-yl)ethane-1,2-diol;
(S)-1-(6-(10-methyl-8-(trifluoromethyl)-10,11-dihydrodibenzo[b,f][1,4]oxazepin-2-yl)pyridin-2-yl)ethane-1,2-diol;
(S)-1-(6-(10-methyl-2-(trifluoromethyl)-10,11-dihydrodibenzo[b,f][1,4]oxazepin-8-yl)pyridin-2-yl)ethane-1,2-diol;
(S)-6-((1-amino-1-oxopropan-2-yl)amino)-2-(10-methyl-8-(trifluoromethyl)-10,11-dihydrodibenzo[b,f][1,4]oxazepin-2-yl)pyrimidine-4-carboxamide;
(2R,3S)-2,3-dihydroxy-3-(6-(10-methyl-8-(trifluoromethyl)-10,11-dihydrodibenzo[b,f][1,4]oxazepin-2-yl)pyridin-2-yl)propanamide; and
(S)-2-(2-(6-(1,2-dihydroxyethyl)pyridin-2-yl)-8-(trifluoromethyl)-dibenzo[b,f][1,4]oxazepin-10(11H)-yl)acetamide;
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 32

(canceled)

### Claim 33 (depends on 2)

A pharmaceutical composition comprising the compound of claim 2, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

### Claim at position 22

34-37. (canceled)

### Claim 38 (depends on 2)

A method for treating pain in mammal, comprising administering an effective amount of a compound as claimed in claim 2, or a pharmaceutically acceptable salt thereof, to a mammal in need of such treatment.

### Claim at position 24

39-40. (canceled)

### Claim 41 (depends on 38)

The method of claim 38, wherein said pain is selected from the group consisting of chronic pain, inflammatory pain, neuropathic pain, acute pain, and surgical pain.

### Claim 42 (depends on 2)

A method of modulating Nav1.7 sodium channel in a mammal, comprising administering to the mammal at least one compound as claimed in claim 2, or a pharmaceutically acceptable salt thereof.

### Claim at position 27

43-45. (canceled)

### Claim 46 (depends on 2)

A compound as claimed in claim 2, or a pharmaceutically acceptable salt or solvate thereof, wherein the compound is 3H, 11C, or 14C radiolabeled.

### Claim 47

(canceled)
